ATLANTA, GA -- October 16, 2006 -- PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the expansion of its confocal imaging capabilities with the introduction of its PhotoKinesis™ accessory. Representing a significant R&D advancement, PhotoKinesis was designed to enable Fluorescence Recovery After Photobleaching (FRAP) and similar techniques on PerkinElmer’s UltraVIEW® Live Cell Imaging systems. The accessory also introduces “Track-It,” on-demand, photoactivation and photoswitching that provides users with greater control over their experiments and increased biologically relevant data from the samples they study.

“The introduction of the PhotoKinesis accessory affirms PerkinElmer’s solid commitment to the confocal microscopy market by bringing FRAP performance to a new level for use in live cell imaging, the fastest-growing segment of the market,” said Mary Duseau, business leader for Detection and Analysis Systems, PerkinElmer Life and Analytical Sciences.

Image Quality of Spinning Disk, FRAP Quality of Point Scanner
“Academic and non-profit research institutions asked for integrated FRAP capabilities with spinning disk technology to improve their ability to study fast-moving objects and rapid events in live cells with point-and-click ease,” Duseau said. “PhotoKinesis in combination with UltraVIEW is an ideal live cell analysis solution.”

UltraVIEW allows users to acquire high-speed, high-resolution, multi-dimensional images of live biological samples including cultured cells, tissues and embryos. The PhotoKinesis accessory further enhances the system’s imaging capability by providing a fully integrated system for studying cells and tissues.

Another key benefit, Duseau noted, is that the low levels of photobleaching present during imaging with UltraVIEW, cause less artifacts in FRAP, Fluorescence Loss in Photo Bleaching (FLIP) and other similar experiments. This leads to simpler and more accurate data interpretation.

Vital to Biomedical Research
FRAP, FLIP and photoswitching techniques are vital to biomedical research because they enable scientists to better understand the basic processes of cellular function and the cellular pathways of a particular disease. Researchers can study disease mechanisms for conditions such as neuro-degeneration, cardiovascular disease, diabetes and cancer. These techniques also enhance developmental studies and general cell biology applications.

The PhotoKinesis accessory will make its U.S. debut at the PerkinElmer booth at the Society for Neuroscience Conference in Atlanta, Oct. 14-17, 2006.

The PhotoKinesis accessory is available globally, with the exception of Japan, as either an upgrade to an existing UltraVIEW ERS or UltraVIEW RS system or it may be purchased with a new UltraVIEW ERS system. For more information on the PerkinElmer PhotoKinesis accessory, visit www.perkinelmer.com/ultraview.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.